The trial judged the tolerability, safety and efficacy of atogepant, at 60 mg once daily, compared to the highest-tolerated ...

Johnson & Johnson (NYSE:JNJ) said that an advisory committee of the EU drug regulator, the European Medicines Agency (EMA), ...

Antibody-drug conjugates, or ADCs, are still holding on to their spot as one of the hottest areas in cancer care—and AbbVie, ...

Eli Lilly LLY and AbbVie ABBV are U.S.-based pharmaceutical powerhouses with blockbuster drug portfolios, robust pipelines, ...

EULAR now recommends moving directly to biologic or targeted synthetic disease-modifying antirheumatic drugs if the initial ...

AbbVie stock danced a wild intraday tango on Tuesday, only to end up flat-footed at the closing bell. The day’s price swing ...

Despite advances, the roles of genetics and microenvironment in CLL are not fully understood, and curative treatments may ...

AbbVie’s migraine drug Atogepant just cleared a major Phase 3 hurdle, and it’s got Wall Street rubbing its temples—in ...

AbbVie said on Wednesday its migraine drug met the main goal and was superior to a widely used generic treatment in a head-to ...

AbbVie's atogepant showed fewer side effects and greater efficacy than topiramate in a Phase 3 migraine prevention trial.

Health and Human Services Secretary Robert F. Kennedy Jr. wants to make it harder and more expensive for drug companies to advertise to patients.

This was the stock's third consecutive day of losses.